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Abstract
© 2018, Pharmainfo Publications. All rights reserved. The aim this study was to investigate the
relationship of polymorphism VEGF gene to the functional state of kidneys in patients with
various phenotypes of obesity. We examined 240 persons (mean age of 43.4±7.3), which were
distributed in several groups. The first group included 90 patients with obesity with metabolic
disorders.  The  second  group  was  presented  by  50  patients-they  do  not  display  signs  of
metabolic disorder. The control group was composed of healthy. We detected high levels of
VEGF in blood and urine, A2, type IV collagen and predominance of minor C allele in group 1. In
group 2, there were VEGF increase in blood and urine (at optimal values of GFR and A1). We
detected a link between polymorphism of promoter region of-634 G/С with levels of SBP, GFR,
A2, type IV collagen and increased expression of VEGF in blood and urine. The increase in VEGF
in the urine reflects the activation of angiogenesis and endothelial dysfunction, aggravated
during the development and progression of chronic kidney disease. In the group with obesity
and hypertension, we detected an increase of VEGF level in urine, while maintaining the normal
range of A and GFR. The distribution of genotypes in the region-634 G/C of VEGF gene revealed
the associating carriage of the minor allele in the group 2. In the group 1, albuminuria 2 was
associated with the CC variant of VEGF gene (-634 G/C).
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